PharmaFocus Today – Page 4 – media

One innovative medical device approved for market launch

Recently, the National Medical Products Administration approved the registration application for the innovative product “intraocular lens with crystalline lens” of Abonod (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as Abonod). Heavy product, breakthrough innovation Established in 2010, iBonod is an innovation driven manufacturer of ophthalmic medical devices, covering three major areas: ophthalmic surgical treatment, myopia prevention and control, and vision health care. We strive to provide one-stop solutions for cataract surgery, refractive error correction, and optical consumption. It is worth mentioning that iBonod successfully listed on the Science and Technology Innovation Board on July 29, 2020, becoming the first ophthalmic medical device company in China to complete the listing on the board. The company is based on three core products: artificial intraocular lenses, corneal reshaping lenses, and contact lenses. The company has strategically expanded its coverage of the entire lifecycle product pipeline for eye health. After years of development, ...
- Source: drugdu
- 56
- January 14, 2025
Sansure Biotech Plans to Acquire 100% Equity of Zhongshan Haiji

Beijing Business News (Reporter Ding Ning) – On January 11, Sansure Biotech (688289) announced that the company intends to acquire 100% equity of Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. (hereinafter referred to as “Zhongshan Haiji”) for 807.5 million yuan. Sansure Biotech stated that Zhongshan Haiji has certain production capacity in the areas of recombinant proteins, peptide technology platforms, as well as overall industrial microbiology and synthetic biology, which can create a synergistic development with the company in the field of functional biomedicine products. In the future, the company will continue to leverage the strengths of both parties to provide technical support and collaborative innovation for the research projects related to growth hormones. Additionally, the expertise in diagnostics can offer necessary validation and feedback support for the ongoing optimization and iteration of growth hormone products. https://finance.eastmoney.com/a/202501123294309388.html
- Source: drugdu
- 53
- January 14, 2025
Confident in China’s Economic Outlook and Development in China, Will Continue to Deepen Commitment to the Chinese Market

On January 9, Ambassador Wang Xuefeng of Denmark met with Lars Fruergaard Jørgensen, Global President and CEO of Novo Nordisk. Ambassador Wang stated that cooperation in the biopharmaceutical and health industry between China and Denmark has been strong, with Novo Nordisk achieving fruitful results in its decades-long partnership with China, leading to mutual benefits. Last July, the 20th Central Committee of the Communist Party of China proposed major reform measures to improve the support mechanism for the development of innovative drugs and medical devices. The Central Economic Work Conference held in December signaled ongoing deepening of reforms and an expansion of high-level opening-up policies. Recently, the Chinese government issued guidance on the high-quality development of the pharmaceutical industry, creating vast opportunities for leading global pharmaceutical companies like Novo Nordisk to develop in China. Ambassador Wang expressed hope that Novo Nordisk would take the occasion of the 75th anniversary of diplomatic ...
- Source: drugdu
- 45
- January 14, 2025
Lowers Novo Nordisk’s Target Stock Price to 875 Danish Krone

Securities Times Network reports that Goldman Sachs has lowered the target stock price for Novo Nordisk to 875 Danish krone (approximately $102.5), but still maintains a “buy” rating. This move is not an isolated case, as both BNP Paribas and Jyske Bank have also reduced their target prices while maintaining an outperform or buy rating. Novo Nordisk’s stock price has fluctuated significantly recently, with some investors expressing disappointment over the performance data of its weight loss drugs. Additionally, UK-based Hikma Pharmaceuticals has received FDA approval to launch a generic version of Novo Nordisk’s diabetes injection, increasing competitive pressure in the market. https://finance.eastmoney.com/a/202501133294434240.html
- Source: drugdu
- 51
- January 14, 2025
No Resistance Found for Baloxavir in China

Roche Pharmaceuticals released a statement saying, “No resistance has been found for Baloxavir in China.” According to authoritative monitoring reports from the World Health Organization (WHO) and the National Centers for Disease Control, Baloxavir currently remains effective against various influenza viruses globally. In China, no strains of the influenza virus exhibiting resistance to Baloxavir have been discovered. The latest data from WHO on the monitoring of antiviral drug-resistant strains show that both Type A and Type B influenza viruses remain sensitive to neuraminidase inhibitors (such as Oseltamivir) and RNA polymerase inhibitors (such as Baloxavir), and treatment remains effective. https://finance.eastmoney.com/a/202501123294373814.html
- Source: drugdu
- 40
- January 14, 2025
36 billion! Stryker swallows up the “peripheral” giant

On January 6, Stryker announced that it would acquire peripheral giant Inari Medical for $80 per share in cash, with a total transaction value of approximately $4.9 billion (approximately RMB 36 billion). The two companies expect to complete the transaction by the end of the first quarter of 2025, but it is subject to the tender of most of Inari’s outstanding shares, regulatory approval and other customary conditions. At the beginning of 2025, the merger and acquisition king Stryker “re-emerged” and threw in a large acquisition case. Behind the first acquisition of the year is the signal that Stryker has officially entered the peripheral vascular market. Why premium acquisitions are favored It is reported that Stryker’s acquisition was a premium acquisition. Before the transaction was announced, Inari Medical’s stock price was about $48, but the actual official acquisition announcement showed that Stryker acquired it at $80 per share in cash. ...
- Source: drugdu
- 62
- January 13, 2025
Domestic bispecific ADCs are authorized to be exported overseas

On January 8, Yingen Bio and Avenzo Therapeutics jointly announced that the two parties have signed an exclusive license agreement. Under the agreement, Avenzo will obtain the exclusive rights to develop, manufacture and commercialize DB-1418/AVZO-1418 worldwide (excluding Greater China). Yingen Bio will receive a down payment of US$50 million and is eligible to receive development, registration and commercialization milestone payments of up to US$1.15 billion. In addition, Yingen Bio is also eligible to receive a share of Avenzo’s sales revenue in its region. It is reported that DB-1418 is an EGFR/HER3 bispecific antibody drug conjugate (ADC) developed by Yingen Bio. It is currently undergoing a new drug clinical trial application (IND) support study and plans to enter the clinical research stage this year. Star Biotech has made another success. According to Yingen Bio’s official information, the company is an innovative biopharmaceutical company in the clinical stage, focusing on the development ...
- Source: drugdu
- 64
- January 13, 2025
Star vaccine may increase risk of rare neurological disease

According to foreign media news, the US FDA requires respiratory syncytial virus (RSV) vaccines produced by Pfizer and GlaxoSmithKline (GSK) to add warnings about the risk of Guillain-Barré syndrome (GBS) on the label. Guillain-Barré syndrome is a rare neurological disease whose cause may be related to infection and immune response. The characteristic symptoms are symmetrical limb weakness, limb numbness, and loss of sensation like wearing gloves and socks, and may cause paralysis. There are currently three RSV vaccines on the market worldwide, namely the recombinant proteins Arexvy (GSK) and Abrysvo (Pfizer), and Moderna’s mRNA vaccine mResvia. The FDA’s regulations involve the first two. The gorgeous opening RSV belongs to the genus Pneumovirus of the family Paramyxoviridae. It is a single-stranded RNA virus that was first isolated from the respiratory tract of chimpanzees in 1956. According to WHO statistics, about 64 million people are infected with RSV each year, and nearly ...
- Source: drugdu
- 55
- January 13, 2025
HPV vaccine changes overnight

Once upon a time, Wantai Bio successfully won the bid for the vaccine procurement project of Jiangsu Government Procurement Network with a price of 86 yuan per dose, which “beat” the price of 2-valent HPV vaccine to less than 100 yuan in one fell swoop, and seized the market with a “discount price”. The 9-valent HPV vaccine is also “not to be outdone”. Merck first expanded the 9-valent HPV vaccine to women aged 9-45 years old, and then signed an exclusive agency agreement with Zhifei Bio with a total amount of over 100 billion yuan, intending to win the Chinese female HPV vaccine market in one fell swoop. On January 8, a new story has begun. Merck announced that several new indications of its quadrivalent human papillomavirus vaccine (brewer’s yeast) have been approved for listing by the National Medical Products Administration and are suitable for vaccination of males aged 9 ...
- Source: drugdu
- 58
- January 13, 2025
One medical device has obtained FDA breakthrough device certification

Recently, the controllable degradation magnesium alloy bone screw developed by Suzhou Innoco Medical Technology Co., Ltd. (hereinafter referred to as Innoco) has been awarded the Breakthrough Device qualification by the US Food and Drug Administration (FDA). It is understood that this is the first biodegradable magnesium alloy orthopedic product in China to pass this certification. Moreover, as the only authoritative certified absorbable orthopedic implant technology enterprise in China, InnoTech has filled this technological gap in the domestic market and broken through the limitations of international similar products in terms of indications. Integrating pioneering technology to solve neck problems Innoco was founded in 2022 and is a high-tech enterprise with innovative technology and independent intellectual property rights. It is committed to the research and industrial transformation of absorbable magnesium alloy materials and advanced orthopedic instruments, and has multiple core technologies such as high-performance magnesium alloy synthesis, controllable degradation composite coating preparation, ...
- Source: drugdu
- 74
- January 10, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.